# Community Health Systems Inc: overview

CYH · NYSE · CIK 1108109 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cyh.md) · [Financials](/companies/cyh/financials.md) · [Filings](/companies/cyh/filings.md) · [Insiders](/companies/cyh/insiders.md)

Latest reported revenue: [$2.76bn](/filings/0001193125-26-437869.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-437869).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,265 d](/filings/0001193125-26-059509.md) | [3,159](/filings/0001193125-26-170557.md) | [3,133](/filings/0001193125-26-314196.md) | [3,087](/filings/0001193125-26-437869.md) | [3,106 d](/filings/0001193125-26-059509.md) | [2,965](/filings/0001193125-26-170557.md) | [2,825](/filings/0001193125-26-314196.md) | [2,757](/filings/0001193125-26-437869.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [8.5% d](/filings/0001193125-26-059509.md) | [9.0%](/filings/0001193125-26-170557.md) | [16.3%](/filings/0001193125-26-314196.md) | [7.9%](/filings/0001193125-26-437869.md) | [14.5% d](/filings/0001193125-26-059509.md) | [9.5%](/filings/0001193125-26-170557.md) | [13.8%](/filings/0001193125-26-314196.md) | [5.3%](/filings/0001193125-26-437869.md) |
| Net margin | % | [(2.1%) d](/filings/0001193125-26-059509.md) | [(0.4%)](/filings/0001193125-26-170557.md) | [9.0%](/filings/0001193125-26-314196.md) | [4.2%](/filings/0001193125-26-437869.md) | [3.5% d](/filings/0001193125-26-059509.md) | [(2.0%)](/filings/0001193125-26-170557.md) | [2.5%](/filings/0001193125-26-314196.md) | [(3.1%)](/filings/0001193125-26-437869.md) |
| Diluted EPS | $ per share | not reported | [(0.10)](/filings/0001193125-26-170557.md) | [2.09](/filings/0001193125-26-314196.md) | [0.96](/filings/0001193125-26-437869.md) | not reported | [(0.43)](/filings/0001193125-26-170557.md) | [0.51](/filings/0001193125-26-314196.md) | [(0.63)](/filings/0001193125-26-437869.md) |
| Free cash flow | $m | [107 d](/filings/0001193125-26-059509.md) | [35.0](/filings/0001193125-26-170557.md) | [(3.0) d](/filings/0001193125-26-314196.md) | [4.0 d](/filings/0001193125-26-437869.md) | [172 d](/filings/0001193125-26-059509.md) | [(373)](/filings/0001193125-26-170557.md) | [12.0 d](/filings/0001193125-26-314196.md) | [67.0 d](/filings/0001193125-26-437869.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [12.4](/filings/0000950170-24-018021.md) | [12.2](/filings/0000950170-25-023242.md) | [12.5](/filings/0001193125-26-059509.md) | [12.6](/filings/0001193125-26-059509.md) | [12.5](/filings/0001193125-26-059509.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [11.3%](/filings/0000950170-24-018021.md) | [6.7%](/filings/0000950170-25-023242.md) | [7.7%](/filings/0001193125-26-059509.md) | [4.3%](/filings/0001193125-26-059509.md) | [11.9%](/filings/0001193125-26-059509.md) |
| Net margin | % | [1.9%](/filings/0000950170-24-018021.md) | [0.4%](/filings/0000950170-25-023242.md) | [(1.1%)](/filings/0001193125-26-059509.md) | [(4.1%)](/filings/0001193125-26-059509.md) | [4.1%](/filings/0001193125-26-059509.md) |
| Diluted EPS | $ per share | [1.76](/filings/0000950170-24-018021.md) | [0.35](/filings/0000950170-25-023242.md) | [(1.02)](/filings/0001193125-26-059509.md) | [(3.90)](/filings/0001193125-26-059509.md) | [3.77](/filings/0001193125-26-059509.md) |
| Free cash flow | $bn | [(0.6)](/filings/0000950170-24-018021.md) | [(0.1)](/filings/0000950170-25-023242.md) | [(0.3)](/filings/0001193125-26-059509.md) | [0.1](/filings/0001193125-26-059509.md) | [0.2](/filings/0001193125-26-059509.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cyh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [CastleKnight Management LP](/funds/1835751.md) | 2026-06-30 | $44.7m | 13,384,586 |  | Added +717,000 |
| [Apollo Management Holdings, L.P.](/funds/1449434.md) | 2026-06-30 | $39.6m | 11,859,526 |  | Added +370,210 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $36.5m | 10,930,538 |  | Added +1,127,681 |
| [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $26.3m | 7,864,575 |  | Reduced −812,706 |
| [NOMURA HOLDINGS INC](/funds/1163653.md) | 2026-06-30 | $22.4m | 6,703,109 |  | Reduced −181,900 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $17.7m | 5,289,931 |  | Reduced −85,572 |
| [WHITEBOX ADVISORS LLC](/funds/1257391.md) | 2026-06-30 | $12.5m | 3,732,743 |  | Added +604,859 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $10.6m | 3,167,702 |  | Added +260,097 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $10.2m | 3,061,863 |  | Added +139,953 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $10.1m | 3,018,598 |  | Added +25,102 |

## Recent filings

[All 1,520 filings](/companies/cyh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:30 ET | [10-Q](/filings/0001193125-26-437869.md) | Quarterly report, period 2026-09-30 | 0001193125-26-437869 |
| 2026-10-28 | 16:30 ET | [8-K](/filings/0001193125-26-436229.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-436229 |
| 2026-07-23 | 16:30 ET | [10-Q](/filings/0001193125-26-314196.md) | Quarterly report, period 2026-06-30 | 0001193125-26-314196 |
| 2026-07-22 | 16:33 ET | [8-K](/filings/0001193125-26-312454.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-312454 |
| 2026-06-01 | 16:30 ET | [8-K](/filings/0001193125-26-251540.md) | 2.01 Completion of an acquisition or disposition; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-251540 |
| 2026-05-13 | 16:30 ET | [8-K](/filings/0001193125-26-221742.md) | 5.07 Shareholder vote results | 0001193125-26-221742 |
| 2026-05-06 | 16:05 ET | [8-K](/filings/0001193125-26-208926.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-208926 |
| 2026-04-23 | 20:20 ET | [8-K](/filings/0001193125-26-171305.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-171305 |
| 2026-04-22 | 16:30 ET | [10-Q](/filings/0001193125-26-170557.md) | Quarterly report, period 2026-03-31 | 0001193125-26-170557 |
| 2026-04-21 | 16:35 ET | [8-K](/filings/0001193125-26-167000.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-167000 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-059509.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/ee635c03-8928-40c9-a47f-0c82d04a8923)

## About the filer

- CIK: 1108109
- Tickers: CYH
- Exchange: NYSE
- SIC code: 8062 Services-General Medical & Surgical Hospitals, NEC
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:46 ET. No prices; not investment advice.